Specialty device maker Insulet (NASDAQ:PODD) had some good news to impart to the world early this week, and investors jumped on the stock as a result. As the market started to prepare for its weekend early Friday, Insulet's share price had risen by almost 11% week to date, according to data compiled by S&P Global Market Intelligence.
New approval granted
Insulet specializes in insulin pumps, and on Monday it formally announced its latest offering in the category had received Food and Drug Administration (FDA) approval for a new indication. This product is the latest iteration of its Omnipod line, the Omnipod 5 Automated Insulin Delivery (AID) System. The FDA approved Omnipod 5 for type 2 diabetes patients 18 years of age and older.
The device had previously been approved for type 1 diabetes. Insulet said that the latest regulatory nod makes Omnipod 5 the only AID to carry FDA approval for both types.
"Insulet is paving the way for these individuals to achieve better health outcomes while living with greater confidence and freedom through the game-changing benefits of tubeless pod therapy," the healthcare device company's CEO, Jim Hollingshead, said.
Large patient population
There is certainly a significant addressable market in this country for that label expansion. According to Insulet, at the moment more than 30 million people suffer from type 2 diabetes. Of this number, roughly 6 million must take insulin treatments. Among that population are 2.5 million people who require multiple daily injections. This is the target market for Insulet, as the Omnipod automatically delivers dosages at regular intervals.
Should you invest $1,000 in Insulet right now?
Before you buy stock in Insulet, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Insulet wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $769,685!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of August 26, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy.
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)